N/A
Completed N=832
Enhancing Community Capacity to Improve Cancer Care Delivery
Source: ClinicalTrials.gov NCT04107116 ↗Enrolled (actual)
832
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcomePrimary: Edmonton Symptom Assessment Scale (ESAS) Symptom Screen — 7; 7 total score on a scale
Summary
Undertreated patient symptoms and resulting acute care use require approaches that improve symptom-burden. Previously a a lay health worker (LHW)-led symptom screening intervention was developed for patients with advanced cancer. This intervention will be expanded to all patients with cancer and the LHW will be trained to refer patients to palliative care and behavioral health. This intervention will evaluate the effect on symptom-burden, survival, healthcare use, and total costs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Edmonton Symptom Assessment Scale (ESAS) Symptom Screen |
7; 9.8 | — |
| PRIMARY Personal Health Questionnaire-9 (PHQ-9) Depression Screen |
1.9; 3.9 | — |
| SECONDARY Incidence of Emergency Department Visits Within 12-months After Patient Enrollment (Chart Review) |
0.43; 0.57 | — |
| SECONDARY Incidence of Hospitalization Visits Within 12 Months After Patient Enrollment (Chart Review) |
0.54; 0.72 | — |
| SECONDARY Number of Patients With a Hospice Consult Within 12-months After Patient Enrollment (Chart Review) |
207; 101 | — |
| SECONDARY Total Health Care Costs (Claims Review) |
17,869; 18,473 | — |
| SECONDARY Number of Patients With an Acute Care Facility Death (Chart Review) |
18; 30 | — |
| SECONDARY Number of Emergency Department Visit in the Last 30 Days of Life (Chart Review) |
0.10; 0.30 | — |
| SECONDARY Number of Hospitalization Visits in the Last 30 Days of Life (Chart Review) |
0.27; 0.43 | — |
| SECONDARY Number of Patients With a Hospice Consult in the Last 30 Days of Life (Chart Review) |
125; 79 | — |
| SECONDARY Total Costs of Care (Claims Review) |
3,602; 12,726 | — |
Eligibility Criteria
Inclusion Criteria
- Newly diagnosed with cancer
- Diagnosis of relapse or progressive disease (any cancer diagnosis) as identified by imaging or biopsy and confirmed by physician.
- Must be 18 years or older.
- Must have capacity to verbally consent
Exclusion Criteria
-Inability to consent to the study due to lack of capacity as documented by the referring physician.
Data sourced from ClinicalTrials.gov (NCT04107116). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.